Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 32,744 Shares
by Scott Moore · The Cerbat GemLiquidia Corporation (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28. Following the completion of the sale, the chief executive officer owned 1,137,599 shares of the company’s stock, valued at $43,649,673.63. This represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Roger Jeffs also recently made the following trade(s):
- On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.
- On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $1,003,000.00.
Liquidia Stock Performance
Shares of NASDAQ LQDA traded down $0.14 during trading hours on Tuesday, reaching $38.71. The stock had a trading volume of 844,813 shares, compared to its average volume of 1,775,539. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -46.64 and a beta of 0.45. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $46.67. The business’s fifty day moving average is $36.87 and its two-hundred day moving average is $32.92. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84.
Liquidia (NASDAQ:LQDA – Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business’s quarterly revenue was up 3072.4% compared to the same quarter last year. As a group, research analysts expect that Liquidia Corporation will post -1.51 EPS for the current year.
Hedge Funds Weigh In On Liquidia
Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Creative Planning raised its stake in shares of Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares in the last quarter. 64.54% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Wells Fargo & Company raised their price target on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Monday, March 23rd. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Needham & Company LLC increased their target price on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. HC Wainwright raised their target price on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.44.
Check Out Our Latest Stock Report on Liquidia
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).